|Brief Description||Principal Investigator|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|To investigate the safety and tolerability of selumetinib when given in combination with MEDI4736 to patients with advanced solid malignancies.||Kim, Edward Sanghyun|
|To compare the incidence of drug-related grade 3 and 4 adverse events of nivolumab 3mg/kg combined with ipilimumab 1mg/kg and nivolumab 1mg/kg combined with ipilimumab 3mg/kg in treatment-naive subjects with unresectable or metastatic melanoma.||Amin, Asim|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.||Amin, Asim|